In vitro activities of trioxaquines against Schistosoma mansoni.
We report the in vitro activities of trioxaquines against larval and adult-stage schistosomes at 5 and 50 microg/ml, respectively. Such activities are equivalent to that of praziquantel, the major and rather unique drug currently used for the treatment of schistosomiasis. In this range of concentrations, artemisinin derivatives (artesunate and artemether) have no activity.
Boissier
Jérôme
J
UMR 5244 CNRS-UPVD-EPHE, Laboratoire de Biologie et d'Ecologie Tropicale et Méditerranéenne, Université de Perpignan, 52 avenue Paul Alduy, 66860 Perpignan, France.
Coslédan
Frédéric
F
Robert
Anne
A
Meunier
Bernard
B
D000634:Aminoquinolines / Q000494:pharmacology*; D000818:Animals; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D007814:Larva / Q000187:drug effects; D051379:Mice; D021261:Parasitic Sensitivity Tests; D012555:Schistosomiasis mansoni / Q000188:drug therapy*; D012556:Schistosomicides / Q000494:pharmacology*
C503429:1,2,4-trioxane; D000634:Aminoquinolines; D006571:Heterocyclic Compounds; D012556:Schistosomicides; C001920:4-aminoquinoline